Literature DB >> 36105336

Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2022        PMID： 36105336      PMCID： PMC9465890          DOI： 10.1021/acsmedchemlett.2c00357

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  3 in total

Review 1.  Androgen blockade based clinical trials landscape in triple negative breast cancer.

Authors:  Yaqin Shi; Fang Yang; Doudou Huang; Xiaoxiang Guan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-25       Impact factor: 10.680

2.  Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers.

Authors:  Amy H Tien; Marianne D Sadar
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

3.  Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib.

Authors:  Wenfei Ji; Yaqin Shi; Xin Wang; Weiwei He; Lin Tang; Shengwang Tian; Hua Jiang; Yongqian Shu; Xiaoxiang Guan
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.